findmyKOL

Jonathan Cho, MD

Basic profile

Hematology / Oncology

ORCIDNone on fileNPI
RegionHonolulu, HI · WestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding2007–2024Why? →

Jonathan Cho is an Oncology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
14companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2007–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1329 Lusitana St Ste 307
Honolulu, HI 968132435

Telephone

808-524-6115

Registry record last updated 18 Jul 2019.

View the NPPES registry record

Industry payments

14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    92.9%
    Aromatase Inhibitor80.5%
    Anastrozole59%Letrozole23%Exemestane18%
    Part D50 patients
    Estrogen Agonist/Antagonist12.3%
    Tamoxifen Citrate100%
    Part D<11 patients
  • Hormonal (systemic)

    7.1%
    l-Thyroxine7.1%
    Levothyroxine Sodium100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 20072024 per NIH RePORTER. The latest:

3 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”